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Abstract
Background: Bone morphogenetic proteins (BMPs) belong to the TGF-β  superfamily and are
secreted proteins with pleiotropic roles in many different cell types. A potential role of BMP-6 in
the immune system has been implied by various studies of malignant and rheumatoid diseases. In
the present study, we explored the role of BMP-6 in normal human peripheral blood B cells.
Results: The B cells were found to express BMP type I and type II receptors and BMP-6 rapidly
induced phosphorylation of Smad1/5/8. Furthermore, Smad-phosphorylation was followed by
upregulation of Id1 mRNA and Id1 protein, whereas Id2 and Id3 expression was not affected.
Furthermore, we found that BMP-6 had an antiproliferative effect both in naïve (CD19+CD27-) and
memory B cells (CD19+CD27+) stimulated with anti-IgM alone or the combined action of anti-IgM
and CD40L. Additionally, BMP-6 induced cell death in activated memory B cells. Importantly, the
antiproliferative effect of BMP-6 in B-cells was completely neutralized by the natural antagonist,
noggin. Furthermore, B cells were demonstrated to upregulate BMP-6 mRNA upon stimulation
with anti-IgM.
Conclusion:  In mature human B cells, BMP-6 inhibited cell growth, and rapidly induced
phosphorylation of Smad1/5/8 followed by an upregulation of Id1.
Background
Members of the transforming growth factor β  (TGF-β )
superfamily play central roles in controlling cellular pro-
liferation, differentiation, migration and apoptosis [1].
These cytokines can be divided into three subgroups: TGF-
β , the activins/inhibins, and the bone morphogenetic pro-
teins (BMPs), of which the latter constitute the largest
family. BMPs are 30–38 kDa hetero- or homodimeric pro-
teins originally identified by their ability to induce ectopic
cartilage and bone formation [2,3]. Several studies have
demonstrated an essential role of these proteins during
embryogenesis, and more recently, also in adult tissues
[1]. TGF-β  has been intensively studied in normal and
malignant haematopoietic cells and is one of the most
potent endogenous negative regulators known to date.
[4]. In contrast, the effect of BMPs in the immune system
has not been widely investigated. In that respect, BMP- 2,
-4 and -7 have been found to control differentiation of
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hematopoietic stem cells [5] and early T cell development
[6,7]. BMP-6 has been reported to reduce the number of
cobblestone-area-forming cells of normal human haemat-
opoietic cells [8]. Furthermore, BMP-2, -4, 6 and -7 had an
antiproliferative and a proapoptotic effect on multiple
myeloma cells [9-11]. In addition, by gene expression
profiling, BMP-6 significantly increased the predictive
value for a multi-gene signature test and was associated
with a poor outcome in diffuse large B cell lymphomas
(DLBCL) [12].
BMP-6, like the other BMP members, signals through liga-
tion and heterodimerzation of BMP type I [activin-like-
kinase (ALK)] and type II serine-threonine kinase recep-
tors, which subsequently propagates the signal down-
stream by phosphorylating Smad proteins. BMP-6 can
signal through the ligation of the type I receptors Act-RIA,
BMP-RIA, and BMP-RIB and the type II receptors BMP-RII,
Act-RIIA and Act-RIIB, which lead to the phosphorylation
of the receptor Smads (Smad-1, Smad-5, and Smad-8).
The R- Smads then form complexes with the co-Smad
(Smad4) and are translocated into the nucleus where they
exert gene regulation [1,13].
Given the reported role of BMP-6 in B-cell malignancies
and haematopoietic progenitor cells, we wanted to
explore its potential role in normal human B cells. We
studied the effects of BMP-6 on proliferation and apopto-
sis on resting and stimulated B cells. Furthermore, the
expression of BMP receptors and BMP-6 induced activa-
tion of the Smad signalling pathway with subsequent reg-
ulation of the target genes Id1–Id4, were resolved. Finally,
we investigated whether B cells also were capable of pro-
ducing BMP-6.
Results
BMP-6 inhibits anti-IgM induced proliferation of human B 
cells
The effects of BMP-6 on normal and neoplastic hemat-
opoietic cells prompted us to investigate the effects of
BMP-6 on normal human B cells. All experiments in this
study were performed under serum-free conditions as FCS
has been shown to interfere with BMP-signalling
[14](own observations). To study the effect of BMP-6 on
proliferation, B-cells from healthy volunteers were stimu-
lated with anti-IgM and/or CD40L in the presence or
absence of BMP-6 for three days. We found that BMP-6 led
to a 35% mean reduction of anti-IgM- induced DNA syn-
thesis (n = 8; p ≤  0.0002, Figure 1A). Similar results were
obtained for B cells treated with anti-IgM and CD40L
(26% mean reduction, n = 6; p ≤  0.023). The BMP-6-
induced inhibition of proliferation was dose-dependent
in both peripheral B cells (Figure 1B) and the Burkitt lym-
phoma cell line Ramos (40% reduction of DNA synthesis,
Figure 1C). The BMP-6 effects could be reversed by addi-
tion of the extracellular inhibitor Noggin (Figure 1D).
Similarly, a combination of the soluble BMP receptors
BMP-RIB-Fc and BMP-RII-Fc also neutralized the effects of
BMP-6 (data not shown). Next, we wanted to test whether
BMP-6 had different effect on naïve and memory B cells.
Naïve (CD19+CD27-) and memory (CD19+CD27+) B cells
were isolated from peripheral blood by cell sorting of
immunobead-isolated CD19+ B cells [15], and tested for
their capacity to proliferate in the presence of BMP-6.
However, BMP-6 inhibited anti-IgM induced DNA syn-
thesis in the two subpopulations to a similar extent, with
a mean reduction of DNA-synthesis of 45% (n = 5; p ≤
0,004) for naïve B cells and 48% (n = 5; p ≤  0,001) for
memory B cells (Figure 1E).
BMP-6 induces cell death in human memory B cells and 
Ramos cells
Next, we wanted to establish whether BMP-6 also could
affect the viability of normal B cells. Cell viability was
determined by propidium iodide (PI) staining after cul-
ture with or without BMP-6 for 48 hours. Interestingly,
BMP-6 showed a small, but reproducible mean increase of
cell death from 17 to 23% (n = 5; p ≤  0,003) in anti-IgM
stimulated CD27+ memory B cells. Furthermore, Ramos
cells showed a mean increase in cell death from 20 to 50%
(n = 3, p < 0,001, figure 3) after BMP-6 treatment. In con-
trast, cell death of total CD19+ cells (n = 6; p ≤  0,32; data
not shown) or CD27-IgG- naïve B cells was not signifi-
cantly affected (n = 5; p ≤  0,65, figure 2).
Human B cells express BMP-6 receptors
Detailed knowledge regarding expression of different
BMP receptors in B cells is currently not available. To fur-
ther elucidate the role of BMPs in human B cells, we per-
formed western blot analysis for type I and type II BMP
receptors. This analysis revealed that the type I receptors
Act-RIA, BMP-RIB and the type II receptors BMP-RII and
Act-RIIb are expressed on resting human B-cells (Figure
4). Ramos cells expressed the type I receptors Act-RIA,
weakly BMP-RIB and the type II receptor BMP-RII, but
more weakly than normal B cells (Figure 4). HL60 cells
were used for comparison and weakly expressed Act-RIA
and BMP-RII.
Taken together, these data show that normal human B
cells and Ramos cells express a set of BMP receptors, pre-
viously shown to bind BMP-6 [16].
BMP-6 induces phosphorylation of Smad1/5/8
Upon ligand binding, the type II receptor transphosphor-
ylates and activates the type I receptor. Type I receptors
can signal via several pathways. We examined the effect of
BMP-6 on Smad phosphorylation, as the activation of
Smad is considered to be a major signalling pathway for
BMPs [17]. B cells were cultured in serum-free media overBMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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night and then treated with BMP-6 for various time
points. Total protein lysates were prepared, and the
amounts of the phosphorylated forms of Smad1/5/8 were
determined by western blot analysis. Interestingly, treat-
ment with 500 ng/ml BMP-6 induced phosphorylation of
Smad. The BMP-6 induced phosphorylation was high at
the earliest time point tested (15 minutes), and remained
high for at least 48 hours (Figure 5). A similar phosphor-
BMP-6 inhibits proliferation of human B cells Figure 1
BMP-6 inhibits proliferation of human B cells. A) CD19+ B cells were isolated from peripheral blood and stimulated in 
triplicates with anti-IgM (37.5 µg/ml) or anti-IgM and CD40 ligand (CD40L; 10 ng/ml) in the presence or absence of BMP-6 for 
72 hours. DNA synthesis was measured by [3H]-thymidine incorporation for the last 18 hours. Data are given as relative pro-
liferation obtained by normalizing the mean counts per minute (cpm) for each stimulation to the mean cpm obtained for anti-
IgM stimulated cells ± SEM. (mean cpm = 25 352 for anti-IgM stimulated cells, *p ≤  0.0002 (n = 8), **p ≤  0.023 (n = 6). B) Dose 
dependent inhibition of BMP-6 of anti-IgM induced DNA-synthesis of CD19+ B cells (relative proliferation ± SEM, n = 3) and C) 
the Burkitt lymphoma cell line Ramos (relative proliferation ± SEM, n = 3). Ramos cells were cultured for 72 hours and [3H]-
thymidine were added for the last 4 hours. D) Noggin (5 µg/ml) and BMP-6 (0,25 or 1 µg/ml) were preincubated for 1 h at 
37°C and then added to the CD19+ B cells in the presence of anti-IgM(37.5 µg/ml). Cells were cultured for 72 h and DNA syn-
thesis was measured by 3H-thymidine incorporation. One representative of three separate experiments is shown (mean cpm ± 
SD of triplicates). E) Highly purified CD19+CD27- or CD19+CD27+ cells were obtained by cell sorting of CD19+ cells and stim-
ulated with anti-IgM in the presence or absence of BMP-6, as indicated for 72 hours. DNA synthesis was measuredby [3H]-thy-
midine incorporation. Data are given as relative proliferation obtained by normalizing the mean cpm for each stimulation to the 
mean cpm obtained for anti-IgM stimulated cells (mean cpm = 18 221 for CD19+CD27- naïve B cells, mean cpm = 8 930 for 
CD19+CD27+ memory B cells, n = 5; * p ≤  0,004, **p ≤  0.001).
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ylation was observed in Ramos cells, but not in HL60 cells
(Figure 6). Furthermore, we also tested whether other
known downstream signalling pathways of BMP-6 could
be triggered by BMP-6 in human B cells. However, we did
not observe any significant changes in the level of phos-
pho-STAT3 or phospho-p38 upon BMP-6 treatment of B
cells (data not shown).
BMP-6 induces upregulation of Id1
Next, we wanted to explore whether the BMP-6 induced
phosphorylation of Smad 1/5/8 also could induce tran-
scriptional changes of target genes. In this regard, the
inhibitors of DNA binding proteins (Ids) are considered
to be some of the major target genes for Smad-signalling
[17]. Thus, B cells were pre-incubated over night in X-
VIVO 15, and then cultured in medium alone or in the
presence of BMP-6 for various time points before prepara-
tion of total RNA. The amount of Id1–Id4  mRNA was
quantified by real-time RT-PCR. Interestingly, we
observed a specific four-fold upregulation of Id1 mRNA in
BMP-6-treated B cells (Figure 7). The up-regulation of Id1
mRNA was characteristic of an early inducible gene, with
maximal upregulation two hours after the addition of
BMP-6 and returned to baseline after 24 hours. In con-
trast, no significant changes were observed for Id2 and Id3
mRNA, whereas Id4-transcripts were not detectable (Fig-
ure 7, data not shown).
Western blot analysis revealed that the BMP-6-induced
upregulation of Id1 mRNA also was correlated with upreg-
ulation of Id1 protein as well. The increase in Id1 protein
level was detectable after one hour and increased until 24
hours after BMP-6 addition, showing a 16-fold upregula-
tion compared with t0 (p ≤  0.020, n = 4) (Figure 8 and 9).
In line with the mRNA data, no consistent change in the
amounts of Id2 and Id3 protein could be observed (Figure
8 and 9). We were able to block the Id1 specific band with
a blocking peptide (data not shown). Taken together,
these data suggest that Id1 could be a possible target gene
for mediating the effects of BMP-6 in human B cells,
whereas Id2 and Id3 not seem to be involved.
BMP-6 production in B cells
The fact that BMP-6 has been reported to act as an auto-
crine stimulator in chondrocytes [18] and ovarium [19],
prompted us to investigate whether normal human B cells
could produce BMP-6  upon stimulation. Ramos cells,
which have been described to express BMP-6  mRNA
endogenously [20], and the T cell line Jurkat, served as
positive and negative controls, respectively. Endogenous
BMP-6 mRNA levels in normal B cells were quantified by
real-time RT-PCR after stimulation with anti-IgM for dif-
ferent time points. Interestingly, the up-regulation of
BMP-6 mRNA was characteristic of an early-to intermedi-
ate inducible gene with maximal upregulation four hours
after the addition of anti-IgM. The level of BMP-6 mRNA
was back to baseline after 24 hours upon stimulation (Fig-
ure 10). Furthermore, both FCS and human AB-serum
induced significant upregulation of BMP-6 mRNA (Figure
BMP-6 induces cell death in B cells Figure 2
BMP-6 induces cell death in B cells. CD19+CD27- naïve 
B cells or CD19+CD27+ memory B cells were cultured for 
48 h with BMP-6 (1 µg/ml) with or without anti-IgM (37.5 µg/
ml). Cell death (PI+ cells) was then measured by flow cytome-
try analysis. Data are shown as mean percentage PI+ cells 
from five independent donors (± SEM; p ≤  0,003).
Ramos cells were cultured in the presence or absense of  BMP-6 (1 µg/ml) for 48 h before analysis of cell death by PI  staining Figure 3
Ramos cells were cultured in the presence or absense of 
BMP-6 (1 µg/ml) for 48 h before analysis of cell death by PI 
staining. Data are shown as mean percentage PI+ cells (± 
SEM, n = 3, p ≤  0,001).BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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11). Interestingly, in a separate study we have found that
normal human T cells do not express BMP-6 mRNA after
activation (Sivertsen et al, manuscript in preparation).
Next, we wanted to detect BMP-6 protein in normal B-
cells and tested various commercially available antibod-
ies. However, in our hands these anti-BMP-6 antibodies
did only recognize the recombinant BMP-6 protein and
not the native protein.
Discussion
Recent studies have demonstrated an important role for
BMP superfamily members in hematopoietic stem cells,
early thymocytes [6,7] and B-cell malignancies [8,11,12],
but a role for BMPs in normal human B cells has previ-
ously not been reported. The present study demonstrated
a significant antiproliferative effect of BMP-6 in peripheral
blood CD19+ B cells. Additionally, BMP-6 induced cell
death in CD27+ memory B cells as well as in a Burkitt lym-
phoma cell line (Ramos). Importantly, BMP-6 induced a
rapid and marked increase in Smad-1/5/8 phosphoryla-
tion. Furthermore, the BMP-6 induced Smad phosphor-
ylation was followed by a selective upregulation of Id1
mRNA and subsequent Id1 protein.
CD19+ B cells express BMP type I and type II receptors Figure 4
CD19+ B cells express BMP type I and type II receptors. Total cell lysates were prepared from the myeloid cell line 
HL60, the cell line Ramos or CD19+ B cells isolated from peripheral blood and analyzed by western blot for expression of BMP 
type I and type II receptors. One representative experiment of four is shown.BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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In the present study, the demonstrated antiproliferative
effect of BMP-6 in anti-IgM treated B cells was significant
and dose-dependent. Importantly, the anti-proliferative
effect of BMP-6 could be completely neutralized by the
use of a natural inhibitor, Noggin. This is in line with oth-
ers, showing that Noggin can function as a BMP-6
BMP-6-induced phosphorylation of Smad1/5/8 in CD19+ B cells and Ramos, but not in HL60 cells Figure 5
BMP-6-induced phosphorylation of Smad1/5/8 in CD19+ B cells and Ramos, but not in HL60 cells. CD19+ B cells, 
or the cell lines Ramos or HL60
were cultured in X-vivo 15 over night before treatment with BMP-6 for 30 minutes, or for the indicated time points before  total cell lysates were prepared Figure 6
were cultured in X-vivo 15 over night before treatment with BMP-6 for 30 minutes, or for the indicated time points before 
total cell lysates were prepared. The amount of phosphorylated Smad 1/5/8 was determined by western-blot analysis. The 
membranes were reprobed for Smad1. One representative experiment of three is shown.BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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antagonist [21,22]. In addition, the combination of solu-
ble BMP-RIB-Fc and BMP-RII-Fc fusion proteins also neu-
tralized the anti-proliferative effect of BMP-6 in human B
cells. Interestingly, as for other TGF family members,
bifunctional effects have also been demonstrated for
BMPs. Whereas several of the BMPs have been shown to
promote proliferation in various cell types including
condrocytes [23], liver [24] and granulosa cells [25], anti-
proliferative effects and induction of apoptosis has been
reported for B and T lineage cells. Similar effects as dem-
onstrated for BMP-6 on human B cells in the present
study, were demonstrated for BMP-2, 4, 6 and -7 in
human myeloma cells [9-11]. Other members of the
BMP-family have also been reported to induce apoptosis,
including in mouse B lineage cells [26]. Additionally,
BMP-4 inhibits thymocyte proliferation [6]. Taken
together, these data suggest that the role of BMPs in the
regulation of proliferation and apoptosis is highly cell
type dependent.
To examine how BMP-6 exerts its functional effects in B
cells, we analysed BMP receptor expression by western
blot analysis. Human peripheral B cells were found to
express the BMP type I receptors Act-RIA and BMP-RIB,
and the type II-receptors BMP-RII and Act-RIIb, which sig-
nal after binding of several BMPs, including BMP-6
[16,13]. To further explore BMP-6 induced signalling,
activation of several pathways is possible. The major sig-
nalling pathway known to date, is activation of R-Smads
[13,27]. In that respect, BMPs have been shown to exert
antiproliferative effects in B lineage cells via phosphoryla-
tion of R-Smad [11,28]. Furthermore, BMP-2 has been
shown to induce activation of STAT3 in myeloma cells [9].
However, phosphorylation of R-Smad was not investi-
gated in that study. BMP-2 has also been shown to induce
phosphorylation of p38 [29]. Thus, phosphorylation of
p38, STAT3 and Smad1/5/8 represent important BMP-sig-
nalling pathways that mediated the effects of BMPs and
even cross-talk between these pathways has been reported
[29,30]. In the present study, we were not able to detect
BMP-6-induced changes in the phosphorylation status of
STAT3 or p38 in human peripheral B cells. Instead, a rapid
and marked phosphorylation of Smad1/5/8 was revealed.
In a parallel study, we have found that other BMPs also
induced phosphorylation of Smad1/5/8 in peripheral B
cells (data not shown). We are currently pursuing micro-
array studies to identify the signalling pathways and target
genes that are differently regulated by the various BMPs in
human B cells.
Upregulation of Id1 via Smad1/5/8 phosphorylation is a
known mechanism for BMP-6 signalling in other cell sys-
tems [31,32] and regulation of Id-proteins is thought to
be an important mechanism for Smad-signalling [17]. In
the present study, real-time RT-PCR experiments revealed
a specific four-fold upregulation for Id1 in BMP-6-treated
B cells, while the amount of Id2–Id4  remained
BMP-6 induced upregulation of Id1 at the mRNA and protein  level Figure 7
BMP-6 induced upregulation of Id1 at the mRNA and 
protein level. CD19+ B cells were cultured in X-vivo 15 
over night before treatment with BMP-6 for the indicated 
time points. Total RNA was extracted and Id1, Id2 or Id3-
expression was analysed by real-time RT-PCR; values are 
normalised to the expression level of PGK1 mRNA and 
expressed as relative quantification (2-average ∆∆ CT – relative 
to Id1, Id2 or Id3 expression in the cell-line Ramos). One rep-
resentative of three independent experiments is shown.
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unchanged. In agreement with this, western blot analysis
demonstrated an upregulation of Id1 protein, while the
amount of Id2 and Id3 protein levels remained
unchanged. Previously, Id1 has been considered not to be
expressed in later developmental stages than pro-B cells
[33,34], and its constitutive expression has been reported
to impair mouse B cell development [35]. Therefore, our
demonstration of the time-dependent upregulation of Id1
mRNA and protein in mature normal human B cells is of
particular interest. In that respect, it is noteworthy that
TGF-β  signalling in early and mature B cells induces both
Id2 and Id3 expression [36,37], but not Id1 (data not
shown). Interestingly, these results show that various
members of the TGF-β  family regulate Id proteins differ-
ently. Id2 and Id3 are considered to be the Id proteins
mainly expressed in mature B cells [38]. The present study
also found Id2 and Id3 protein in B cells to be more highly
expressed than Id1 in resting B cells. However, BMP-6 did
not induce significant changes in the protein expression of
Id2 and Id3. It is believed that Id proteins block differen-
tiation and promote proliferation in various cell types
[39,33]. Id proteins act as dominant-negative inhibitors of
E-proteins and Pax5 function by forming dimers with
these proteins, making them unable to bind DNA. It has
been proposed that the balance among E-proteins, Pax5
and Id proteins might have an important role in activated
B cells [38]. In that respect, E-proteins have been impli-
cated in both the promotion and inhibition of cell sur-
vival and growth at different points in lymphocyte
development [40]. The antiproliferative and death induc-
ing effect of BMP-6 in B cells with concomitant upregula-
tion of Id1 protein is therefore in line with the view that
Id proteins are required for the induction of growth arrest
and apoptosis in B-lymphocyte progenitors by TGF-β
[40].
Furthermore, Id proteins are known as important parts of
signalling pathways involved in development, cell cycle
and tumorigenesis [32]. It is well established that various
members of the Id family are overexpressed in a range of
human tumours and generally, Id1 appears to be the fam-
ily member most widely overexpressed in a variety of
human malignancies [41], including multiple myeloma
[42,32]. Additionally, our findings that BMP-6 activates
intracellular signalling pathways in human B cells might
be of potential pathophysiological significance in lym-
phoma and inflammation. High BMP-6 mRNA expression
in DLBCL has been shown to correlate to unfavourable
outcome [12]. In this respect, it is of interest that targeted
expression of Id1 to B-lymphocytes resulted in aberrant B
Id protein expression was determined by western-blot analysis Figure 8
Id protein expression was determined by western-blot analysis. CD19+ B cells were cultured in X-vivo 15 over night before 
treatment with BMP-6 for the indicated time points and cell lysates were prepared. One representative experiment of three is 
shown. HeLa cells were used as a positive control for Id1 protein detection.BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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cell development, massive apoptosis, and subsequent
development of B cell lymphomas [35]. Moreover, BMP-
6 has been suggested to play a role in rheumatoid arthritis
(RA) [43,44] and elevated levels of Id1 and Id3 have been
found in the synovia of RA-patients [45]. Altogether, these
results point to an important role for Id proteins in the
regulation of normal B cell homeostasis and in diseases,
where B cells are involved. It will therefore be important
to further elucidate the role of Id-1 in human B cells by
selective over expression or inhibition of Id-1 gene
expression.
Given the role of BMP-6 in mature human B cells demon-
strated here, identification of BMP-6 producing cells in
vivo with possibility of interaction with naïve and mem-
ory B cells might contribute to the understanding of
mature B cell biology. High BMP-6 mRNA expression in
DLBCL has been detected by gene expression profiling
[12]. Furthermore, production of BMP-6  transcripts in
normal activated B cells was detected in the same study.
Of note, an autocrine BMP-6 loop has been reported by
others in chondrocytes and in the ovarium [46,19,18].
Therefore, we wanted to explore the possibility for an
autocrine BMP-6 loop in human B cells. We analysed the
expression BMP-6 mRNA in peripheral blood B cells by
Relative protein expression of Id1, Id2 and Id3 Figure 9
Relative protein expression of Id1, Id2 and Id3. Quantifica-
tions of Id1, Id2 and Id3 protein levels were performed using 
β -actin as normalization and expressed as mean ± SEM (Id1: 
n = 4, *p ≤  0.020; Id2 and Id3: n = 3).
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Anti-IgM rapidly upregulates BMP-6 mRNA expression in  human B-cells Figure 10
Anti-IgM rapidly upregulates BMP-6 mRNA expres-
sion in human B-cells. CD19-positive B cells were cul-
tured in X-vivo 15 over night and stimulated with anti-IgM 
for the indicated time periods, before total RNA was 
extracted. The expression of BMP-6 mRNA by realtime RT-
PCR; values are normalised to the expression level of PGK1 
mRNA and expressed as relative quantification (2-average 
∆∆ CT – relative to BMP-6 expression in the cell-line Ramos. 
One representative of five independent experiments is 
shown.BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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real-time PCR, and report here the upregulation of
endogenous BMP-6 transcripts after stimulation with FCS,
human AB-serum and, most importantly, anti-IgM. How-
ever, our attempts to study BMP-6 protein levels were
unsuccessful due to problems with unspecific binding of
the anti-BMP-6 antibodies tested, and lack of specific
staining in control cells known to express BMP-6 mRNA.
In contrast, the recombinant protein was readily detected.
In that respect, few investigators have detected BMP-6 pro-
tein in humans, especially in non-pathogenic tissue. The
possibility of BMP-6 production in human B-cells is in
line with a recent work that reported the production of
BMP-6 in mouse B cells, infiltrating the bone marrow of
mice with inflammatory arthritis [43]. In this study, a role
for BMPs in the inflammatoric process of arthritis was sug-
gested. The upregulation of the BMP-6-transcripts after
IgM-crosslinking is of pathophysiologic interest [12]. A
loss of TGF-β -responsiveness has been suggested to be a
critical contribution to malignant transformation [47,48]
and similar oncogenic mechanisms have been postulated
for BMPs. Lines of evidence suggest [49] that at early
stages of carcinogenesis, BMP-6 is not a tumour promoter,
but suppresses benign and malignant tumour outgrowth.
These findings are in good agreement with previous
findings for other TGF-β  family members, including TGF-
β 1 and BMP-4 [50], indicating that cellular context of the
BMP target cell might define the various observed effects.
In contrast to the upregulation of BMP-6 transcript in B
cells, we were not able to detect BMP-6  transcripts in
human peripheral blood CD4+ or CD8+ T cells (resting or
stimulated with anti-CD3 and anti-CD28; data not
shown), consistent with the findings in T cell lines [20]
and T cells in mice [43]. Other potential BMP-6 sources
for mature B cells in vivo might be other cells of the
immune system or tissue with contact to the hematopoi-
etic system. One well recognized source for BMP-6 pro-
duction is the human bone and bone marrow stroma
[51,8]. Furthermore, it is noteworthy that human
umbilical vein endothelial cells (HUVEC) highly express
BMP-6 mRNA [52], and vascular endothelium has been
reported to produce BMP-6 [53]. These studies might
imply a role for BMP-6 in transendothelial migration of B
cells.  BMP-6  mRNA has been demonstrated in murine
macrophage cell lines, but not in humans [54]. In accord-
ance with these findings, other human cell lines of neu-
trophil and monocytic origin have been described to be
negative for the BMP-6 transcript [20]. To our knowledge,
there is currently no report about BMP-6 production of
human dendritic cells.
Conclusion
In conclusion, our results show that BMP-6 induces acti-
vation of intracellular Smad signalling in mature human
B-cells with consecutive production of Id1 protein.
Furthermore, we report that BMP-6 has an antiprolifera-
tive effect in B cells stimulated with anti-IgM alone or the
combined action of anti-IgM and CD40L. Additionally,
BMP-6 induces cell death in activated memory B cells and
Ramos cells. Taken together, these results provide a
rationale to further examine the role of BMP-6 signalling
in normal B cell biology as well as in pathologic condi-
tions like B cell malignancies and autoimmune disorders.
Methods
Cell culture
If not specified, all cells were cultured in X-VIVO 15™
(BioWhittaker, Verviers, Belgium) serum-free medium at
37°C and 5% CO2 in air.
Peripheral blood was provided by the Blood Bank at
Buskerud Regional Hospital with formal agreement by the
patients, and approval by the regional ethics committee.
Highly purified resting human B-lymphocytes (CD19+
cells) were isolated from the peripheral blood by rosetting
with immunomagnetic beads (Dynabeads M450; Dynal,
Oslo, Norway) as described [55]. This procedure yields
less than 0.5% T cells, 0.1% NK cells, and 0.5% mono-
cytes as judged by indirect immunofluorescence staining.
The following cell lines from human lymphoid malignan-
cies were maintained in RPMI 1640 (PAA Laboratories
Fetal calf serum and human AB serum upregulates BMP-6  mRNA expression in human B-cells Figure 11
Fetal calf serum and human AB serum upregulates 
BMP-6 mRNA expression in human B-cells. CD19-
positive B cells were cultured in X-vivo 15 over night and 
with fetal calf serum or human AB serum at the indicated 
dilutions for four hours, before total RNA was extracted. 
The expression of BMP-6 mRNA by realtime RT-PCR; values 
are normalised to the expression level of PGK1 mRNA and 
expressed as relative quantification (2-average ∆∆ CT – relative 
to BMP-6 expression in the cell-line Ramos. One representa-
tive of three independent experiments is shown.BMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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GmbH, Pasching, Austria) supplemented with 10% foetal
bovine serum (FCS), 100 units/ml penicillin G, and 100
units/ml of streptomycin sulphate, but serum-starved for
at least four hours and cultured in X-VIVO 15™ when
included in experiments: EBV-negative BL cell lines
Ramos (ECACC 85030802), HL60 (JCRB0085).
Growth factors/supplements
The following reagents were used at indicated concentra-
tions: recombinant human (rhu) BMP-6 (1 µg/ml, if not
specified otherwise), rhu BMP-RIB/ALK-6/Fc Chimera (5
µg/ml), rhu BMPR-II/Fc Chimera (5 µg/ml), and recom-
binant mouse Noggin (5 µg/ml) were purchased from
R&D Systems (Abingdon, UK); Anti-IgM F(ab)2
fragments of rabbit polyclonal antibodies to human IgM
heavy chain (37.5 µg/ml) was obtained from Dako,
Copenhagen, Denmark and rhu CD40 ligand (CD40L, 10
ng/ml) was a gift from Immunex Corp. (Seattle, WA).
Antibodies used for flow cytometric analysis and 
immunoblot analysis
Antibodies against the human BMP-receptors Act-RIA,
BMP-RIB, BMPR-II, Act-RIIA and Act-RIIb were purchased
from R & D Systems (Abingdon, UK). Detection of the
BMP-6-protein has been tried with the following antibod-
ies: goat polyclonal anti-BMP-6 (Santa Cruz, San Diego,
CA, USA), monoclonal mouse anti-BMP-6 and polyclonal
goat anti-BMP-6 from R & D Systems (Abingdon, UK),
and mouse monoclonal anti-BMP-6 (Chemicon Interna-
tional Inc, Temecula, CA, USA).
Characterisation of BMP-signalling pathways was done by
use of anti-phospho-Smad1, -5, -and 8 polyclonal anti-
body (Chemicon, Temecula, CA, USA). Expression levels
of Id1–3 proteins were detected with polyclonal rabbit
antibody and detection was blocked with blocking
peptide from Santa Cruz Biotechnology (Santa Cruz, San
Diego, CA, USA). As secondary antibodies served anti-
mouse, anti-goat or anti-rabbit IgG- horseradish peroxi-
dase (HRP) from Dakocytomation AS (Copenhagen, Den-
mark) for immunoblot analysis. Anti-β -actin was from
Santa-Cruz. From Becton Dickinson (San Jose, CA), we
purchased anti-CD19-PE, anti-CD19-FITC. The antibod-
ies used for cell sorting were anti-CD19 PC5 from Immu-
notech SA (Marseille, France) and anti-CD27 PE from
Becton Dickinson, Biosciences Pharmingen (San Diego,
CA, USA).
Cell sorting
Highly purified CD19+CD27- or CD19+CD27+ cells were
obtained by staining CD19+ cells with anti-CD27 PE and
CD19 PC5 mAbs for 30 minutes at 4°C, followed by
washing with PBS and sorting on FACS DiVa from Becton
Dickinson.
Western-blot analysis
B cells from peripheral blood or cultured cell-lines were
lysed in lysis buffer (glycerol 10%, β -mercaptoethanol
5%, 0.0625 M Tris-HCL [pH 6.8], sodium dodecyl sul-
phate [SDS] 2.5%w/vol). Total protein (30–100 µg) from
each sample was run on 10% or 12% SDS/polyacrylamide
(SDS/PAGE) gels and blotted onto nitrocellulose filters
(Protran; Schleicher &Schuell GmbH, Dassel, Germany).
Blocking, washing and incubation of the filters with pri-
mary antibodies were done according to the manufac-
turer's protocols at room temperature (RT). After washing
with TBS/0.1% Tween-20 (TBS-T), the filters were incu-
bated with horseradish peroxidase (HRP) coupled to rele-
vant secondary antibodies (see above) for 60 minutes at
RT. Enzyme activity was visualised by the enhanced
chemiluminescence system, ECL+PLUS (Amersham,
Buckinghamshire, UK). Densitometric analysis was per-
formed by scanning hyperfilms on a Personal Densitome-
ter SI (Molecular Dynamics, Sunnyvale, CA).
Quantification of Id1, Id2 and Id3 protein was calculated
by normalizing the specific protein bands to β -actin using
Image Quant 5.5 software (Molecular Dynamics).
Analysis of BMP-6 messenger RNA (mRNA) expression
Endogenous expression of the BMP-6 gene was examined
by reverse transcription-polymerase chain reaction. Total
RNA was isolated using Absolutely RNA™ RT-PCR Mini-
prep Kit (Stratagene Europe, Amsterdam, Netherland)
according to the manufacturers instructions. Quantifica-
tion of the isolated total RNA was achieved by using spec-
trophotometric OD260 measurements. Equal amounts of
RNA were then reverse transcribed to cDNA with TaqMan®
Reverse Transcription Reagents (Applied Biosystems, Fos-
ter City, CA, U.S.A). To measure mRNA expression of
BMP6, Id1–Id4 and PGK1 PCR were carried out with Taq-
Man® universal master mix. Primers and probes were pro-
vided by Assay-on-Demand (Applied Biosystems). PCR
reactions were carried out in a final volume of 25 µl (BMP-
6) or 20 µl (ID1). The cDNA added to each reaction was
equivalent to the input of 20 ng of total RNA. The gene
expression was quantified using the standard curve
method (BMP6), or the comparative CT method (Id1) as
described in ABI7700 User Bulletin 2 (Applied
Biosystems). The expression was then normalized to the
expression level of PGK1. PGK1 was chosen, because it
has been shown to have low expression variability among
lymphocyte specimens [56]. Expression levels in B cells
were then related to the expression levels in Ramos cells.
Cell proliferation
For estimation of DNA synthesis, CD19+ cells (7.5 × 104
cells/0.2 ml) or Ramos cells (1 × 104 cells/0.2 ml) were
cultured in triplicate in microtiter wells. The cells were
pulsed with 3.7 × 104Bq [3H]thymidine (Amersham,
Buckinghamshire, UK) for the last 16 h of a 72-hBMC Immunology 2005, 6:9 http://www.biomedcentral.com/1471-2172/6/9
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incubation. The cells were harvested using an automated
cell harvester (Packard Instrument Company, Meriden,
CT, USA) and [3H]thymidine incorporation was
determined in a scintillation counter (TopCount, Packard
Instrument Company Inc., Meriden, CT).
Determination of cell death
Cell death was measured by vital dye exclusion test by
staining cells with 5 µg/ml propidium iodide ([PI]; Calbi-
ochem Corp.; La Jolla, CA; 5 mg/ml) for one minute on
ice. At least 1,000 cells per sample were run on a BD FAC-
SCalibur flow cytometer.
Statistical analysis
The statistical significance of differences between groups
was determined using the paired two-tailed Wilcoxon
nonparametric test, by applying SPSS10.1 software (SPSS
Inc., Chicago, IL, USA). P values less than 0.05 were con-
sidered significant.
List of abbreviations
BMP, Bone morphogenetic protein
DLBCL, diffuse large B cell lymphoma
Id, inhibitor of dna binding
Smad, the name Smad originates from the Drosophila pro-
tein, MAD and the Caenorhabditis elegans proteins, sma-2,
3 and 4
STAT, signal transducer and activator of transcription
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